This inventor holds 2 USPTO granted patents. Top assignees: University of Iowa Research Foundation, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 925 
1 out of 3,696 
Years Active: 2008
Title: Lynda S Ostedgaard: Innovator in Genetic Therapies
Introduction
Lynda S Ostedgaard is a prominent inventor based in Iowa City, IA (US). She has made significant contributions to the field of genetic therapies, particularly in the treatment of cystic fibrosis. With a total of 2 patents, her work has the potential to impact the lives of many individuals suffering from genetic disorders.
Latest Patents
Ostedgaard's latest patents include innovations related to truncated CMV promoters and vectors containing the same. The first patent focuses on nucleic acid molecules that comprise certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter. These molecules can be operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention is particularly useful for treating a variety of genetic, metabolic, and acquired diseases, including cystic fibrosis (CF) airway disease. The second patent offers new therapies for treating cystic fibrosis based on novel DNA molecules and proteins encoded by these molecules. It features DNA molecules encoding CFTR with a partially deleted R domain, specifically between residues 708 and 835 of the wild-type CFTR.
Career Highlights
Throughout her career, Ostedgaard has worked with esteemed institutions such as the University of Iowa Research Foundation and the National Institutes of Health (NIH). Her research has focused on developing innovative solutions for genetic disorders, showcasing her dedication to advancing medical science.
Collaborations
Ostedgaard has collaborated with notable colleagues, including Michael J Welsh and Mark F Stinski. These partnerships have further enriched her research and contributed to her success in the field.
Conclusion
Lynda S Ostedgaard is a trailblazer in the realm of genetic therapies, with her patents paving the way for new treatments for cystic fibrosis. Her work exemplifies the impact of innovation in addressing complex medical challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile